Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
DUALITY BIOTHERAPEUTICS Aktie jetzt für 0€ handeln | |||||
17.09. | DUALITYBIO-B (09606): 2025 INTERIM REPORT | 5 | HKEx | ||
05.09. | DUALITYBIO-B (09606): INSIDE INFORMATION - PRIMARY ENDPOINT MET FOR PHASE III CLINICAL TRIAL OF DB-1303/BNT323 IN PATIENTS WITH HER2-POSITIVE UNRESECTABLE ... | 19 | HKEx | ||
26.08. | DUALITYBIO-B (09606): INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2025 | 8 | HKEx | ||
14.08. | DUALITYBIO-B (09606): DATE OF BOARD MEETING | 1 | HKEx | ||
22.07. | Duality Biotherapeutics: DualityBio's Next-Generation HER3 ADC DB-1310 Granted FDA Fast Track Designation | 509 | PR Newswire | SHANGHAI, July 21, 2025 /PRNewswire/ -- DualityBio (HKEX Stock Code: 9606.HK) announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track... ► Artikel lesen | |
22.07. | DUALITYBIO-B (09606): VOLUNTARY ANNOUNCEMENT - KEY PRODUCT DB-1310 GRANTED U.S. FDA FAST TRACK DESIGNATION | 2 | HKEx | ||
09.07. | Duality Biotherapeutics: First Patient Dosed in Phase 1/2 Clinical Study of Novel EGFR/HER3 Bispecific Antibody-Drug Conjugate AVZO-1418/DB-1418 | 363 | PR Newswire | SHANGHAI, July 9, 2025 /PRNewswire/ -- Duality Biotherapeutics' ("DualityBio", HKEX:09606) partner Avenzo Therapeutics, Inc. ("Avenzo"), a clinical-stage biotechnology company developing... ► Artikel lesen | |
20.06. | DUALITYBIO-B (09606): POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON JUNE 20, 2025 | - | HKEx | ||
10.06. | DUALITYBIO-B (09606): ANNOUNCEMENT MADE PURSUANT TO RULE 13.10 OF THE LISTING RULES | 1 | HKEx | ||
05.06. | Duality Biologics: Preliminary Data from Two Clinical Trials with ADC Candidates were Presented Orally at the 2025 ASCO Annual Meeting | 535 | PR Newswire | SHANGHAI and CHICAGO, June 5, 2025 /PRNewswire/ -- The 2025 ASCO Annual Meeting is taking place in Chicago, US, from May 30 to June 3. Duality Bio (HKEX: 9606.HK) presented the preliminary... ► Artikel lesen | |
28.05. | DUALITYBIO-B (09606): FORM OF PROXY FOR THE ANNUAL GENERAL MEETING TO BE HELD ON JUNE 20, 2025 | - | HKEx | ||
28.05. | DUALITYBIO-B (09606): NOTICE OF ANNUAL GENERAL MEETING | - | HKEx | ||
28.05. | DUALITYBIO-B (09606): (1) PROPOSED GRANTING OF GENERAL MANDATE TO REPURCHASE SHARES; (2) PROPOSED GRANTING OF GENERAL MANDATE TO ISSUE SHARES (INCLUDING ... | 1 | HKEx | ||
23.05. | Duality Biotherapeutics: FDA Clearance of Investigational New Drug Application Received for Novel EGFR/HER3 Bispecific Antibody-Drug Conjugate AVZO-1418/DB-1418 | 173 | PR Newswire | Phase 1/2 first-in-human clinical study planned this year
SHANGHAI and SAN DIEGO, May 22, 2025 /PRNewswire/ -- Duality Biotherapeutics ("DualityBio", HKEX:09606)... ► Artikel lesen | |
22.05. | Jefferies sets Duality Bio stock Buy rating, HK$500 PT | 4 | Investing.com | ||
12.05. | DUALITYBIO-B (09606): STABILIZING ACTIONS AND END OF STABILIZATION PERIOD | 1 | HKEx | ||
09.05. | DUALITYBIO-B (09606): NEXT DAY DISCLOSURE RETURN | - | HKEx | ||
06.05. | DUALITYBIO-B (09606): FULL EXERCISE OF THE OVER-ALLOTMENT OPTION | - | HKEx | ||
06.05. | XFRA NEW INSTRUMENTS AVAILABLE ON 06.05.2025 | 610 | Xetra Newsboard | The following instruments on XETRA do have their first trading 06.05.2025 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 06.05.2025
Aktien
1 KYG2929M1087 Duality Biotherapeutics... ► Artikel lesen | |
29.04. | DUALITYBIO-B (09606): 2024 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT | - | HKEx |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
BIONTECH | 90,45 | +0,06 % | Achtung Übernahmen! BioTechs wie Evotec, PanGenomic Health, Pfizer und BioNTech im Fokus | Die BioTech-Branche ist in Aufruhr! Mit dem Wegfall von Blockbuster-Patenten drohen kräftige Umsatzrückgänge, die strategisch kompensiert werden müssen. Angetrieben durch wirtschaftlichen Druck und... ► Artikel lesen | |
PALATIN TECHNOLOGIES | - | - | PALATIN TECHNOLOGIES INC - S-1/A, General form for registration of securities | ||
DEFENCE THERAPEUTICS | 0,467 | +1,08 % | Defence Therapeutics Inc.: Defence Therapeutics Appoints Dr. Mark Lambermon as Head of Quality and Operations | Montreal, Quebec--(Newsfile Corp. - October 2, 2025) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a leading biotechnology company specialized in drug... ► Artikel lesen | |
CYTOMX THERAPEUTICS | 2,700 | -1,17 % | CytomX: Wie geht's hier jetzt weiter? | Die Immuntherapie gegen Krebs entwickelt sich stetig weiter, und CytomX Therapeutics gehört zu den Unternehmen, die mit innovativen Ansätzen neue Maßstäbe setzen wollen. Die sogenannte "Probody"-Technologie... ► Artikel lesen | |
ADMA BIOLOGICS | 14,660 | +0,89 % | ADMA Biologics, Inc.: ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update | 2Q 2025 Total Revenue of $122.0 Million, a 14% YoY Increase, and a 29% YoY Increase Excluding a Prior Year Non-Recurring Item 2Q 2025 GAAP Net Income of $34.2 Million, a 7% YoY Increase 2Q 2025 Adjusted... ► Artikel lesen | |
QIAGEN | 39,740 | +0,68 % | Kaum Impulse für die Qiagen NV-Aktie (37,58 €) | Wenig Kursbewegung zur Stunde bei dem Anteilsschein von Qiagen NV . Der jüngste Kurs betrug 37,58 Euro. Einen minimalen Wertanstieg von 0,17 Prozent zeigt die Kurstafel für der Anteilsschein von Qiagen... ► Artikel lesen | |
CG ONCOLOGY | 39,820 | -0,09 % | CG Oncology Inc.: CG Oncology Completes Enrollment in PIVOT-006 | - Rapid enrollment underscores high unmet need in intermediate-risk non-muscle invasive bladder cancer (NMIBC) -- One of the largest randomized phase 3 studies in this patient population will encompass... ► Artikel lesen | |
RECURSION PHARMACEUTICALS | 5,480 | -0,72 % | Recursion Pharmaceuticals: Recursion Reports Second Quarter 2025 Financial Results and Provides Business Update | SALT LAKE CITY, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, today reported business updates and... ► Artikel lesen | |
ARVINAS | 9,610 | +3,61 % | Arvinas Inc.: Arvinas to Present Clinical Data for ARV-102, a PROTAC LRRK2 Degrader, at the 2025 International Congress of Parkinson's Disease and Movement Disorders | ||
IMMUNOME | 12,380 | +7,93 % | Where Immunome Stands With Analysts | ||
JANUX THERAPEUTICS | 24,000 | +3,05 % | Janux Therapeutics: Günstige Gelegenheit | Janux Therapeutics hat mit seiner innovativen Plattformtechnologie im letzten Jahr das Interesse vieler Investoren geweckt - nicht zuletzt aufgrund von Übernahmegerüchten. Doch unabhängig von einem... ► Artikel lesen | |
ARS PHARMACEUTICALS | 10,310 | +0,29 % | ARS Pharma secures $250M loan to accelerate Neffy rollout | ||
TAYSHA GENE THERAPIES | 4,770 | -2,25 % | Taysha Gene Therapies, Inc.: Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | DALLAS, Oct. 03, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based... ► Artikel lesen | |
EVOTEC | 6,744 | +2,00 % | Rheinmetall Aktie: Große Chance? - ABO Energy, Evotec, Funkwerk, MPC Capital und Redcare Pharmacy im Marktbericht Börse Frankfur | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
MOONLAKE IMMUNOTHERAPEUTICS | 8,470 | +13,54 % | Aktien Europa: Leichte Gewinne zum Wochenauftakt | AMSTERDAM/LONDON/PARIS/ZÜRICH (dpa-AFX) - Europas wichtigste Aktienmärkte starten am Montag zunächst freundlich in die neue Woche. Allerdings blieb die Risikobereitschaft verhalten angesichts der bleiben... ► Artikel lesen |